Department of Population Medicine and Diagnostic Sciences


Laura Goodman

Laura GoodmanResearch associate in Molecular Diagnostics and Virology
Animal Health and Diagnostic Center, Cornell University


Department of Population Medicine and Diagnostic Sciences
College of Veterinary Medicine
Cornell University
Ithaca, New York 14853
607-253-3631
laura.goodman@cornell.edu

Research Interests

My research investigates mechanisms of virus emergence in different veterinary models, focusing on host-pathogen interactions in herpesviruses. I have taken a molecular epidemiology approach to identify the genetic variations in viruses and their hosts that contribute to virulence. Correlates of immunity and immune evasion are also central themes from both a basic and applied perspective. I am interested in the diagnosis and prevention of animal disease and its relevance to public health, economics, and animal welfare.


Education

  • 2007  Ph.D., Cornell University, Comparative Biomedical Sciences: Infectious disease-virology, with minors in epidemiology and microbiology


Research and Professional Experience

  • 2013-pres. Research Associate in Molecular Diagnostics and Virology, Cornell University Animal Health Diagnostic Center/Population Medicine and Diagnostic Sciences. Assay development and adaptation of platforms to next-generation technologies.
  • 2011-2013. Postdoctoral Associate, Wagner Lab and Serology/Immunology diagnostic section, Cornell University Dept. of Population Medicine and Diagnostic Sciences. Worked on correlates of immune protection using serology-based assays in emerging infectious disease models (including lyme disease and EHV-1).
  • 2010-2011 Research Fellow, Cantor Lab, Dana-Farber Cancer Institute and Harvard Medical School Dept. of Pathology. Molecular pathology of variant MHC alleles in transgenic mouse models. Studied mechanisms for impairment of virus antigen recognition by murine T cells harboring a mutation in the homolog of human leukocyte antigen E. For these studies, I worked on the prototypic host-switching arenavirus, lymphocytic choriomeningitis virus (LCMV).
  • 2007-2010 Postdoctoral Associate/Fellow, Parrish Lab, Cornell Baker Institute for Animal Health. Worked on the canine parvovirus model of host switching, specifically transferrin receptor binding and directed evolution of antibodies using yeast surface display.
  • 2003-2007 Graduate Research Assistant, Osterrieder Lab, Cornell Dept. of Microbiology & Immunology. Studied the neuropathogenesis and molecular epidemiology of equine herpesvirus type 1 (EHV-1) in both the mouse model and the primary host.
  • 2002-2003 Laboratory Technologist-Research, McCarver Lab, Birth Defects Research Center at the Medical College of Wisconsin. Worked on a prospective epidemiological study to evaluate infant susceptibility to fetal alcohol syndrome and congenital heart disease. Developed an in vitro functional assay for the biomarker (promoter deletion) under study.
  • 2000-2001 Undergraduate Research Assistant, Meshnick Lab, University of Michigan School of Public Health. Studied the immunological effects of co-infection from HIV and malaria during pregnancy. Optimized protocols for extraction and analysis of RNA from placental tissue for malaria and HIV studies, including molecular strain-typing of malaria parasites.
  • 1999 Research Assistant, Brunengraber Lab, Case Western Reserve University. Tested the bioavailability and metabolism of candidate cytostatic compounds in rats and dogs.


    Honors and Awards
  • 2009 Individual NIH Ruth L. Kirschstein National Research Service Award (F32)
  • 2003-06 Institutional NIH Ruth L. Kirschstein National Research Service Award (T32) appointment
  • 2002 University Honors from the University of Michigan, Ann Arbor
  • 1999 Class Honors from the University of Michigan, Ann Arbor


    Professional Memberships
  • American Society for Virology (ASV)
  • American Association of Immunologists (AAI)
  • American Association of Veterinary Laboratory Diagnosticians (AAVLD)


    Selected Publications
  1. Wagner B, Goodman LB, Rollins A, Freer H. Antibodies to OspC, OspF and C6 antigens as indicators for infection with Borrelia burgdorferi in horses. Equine Veterinary Journal. In Press.
  2. Kaelber JT, Demogines A, Harbison CE, Allison AB, Goodman LB, Ortega AN, Sawyer SL, Parrish CR. Evolutionary reconstructions of the transferrin receptor of Caniforms supports canine parvovirus being a re-emerged and not a novel pathogen in dogs. PLoS Pathogens 8(5): Epub 2012 May 3.
  3. Goodman LB, Wimer C, Gold C, Dubovi EJ, Wagner B. Immunological correlates of vaccination and infection for equine herpesvirus type 1. Clinical and Vaccine Immunology 2012 Feb;19(2):235-41.
  4. Goodman LB, Lyi SM, Johnson NC, Cifuente JO, Hafenstein S, Parrish CR. The binding site on the transferrin receptor for the parvovirus capsid, and the effects of altered affinity on cell uptake and infection. Journal of Virology 2010; 84(10):4969-78
  5. Perkins GA, Goodman LB, Tsujimura K, Van de Walle GR, Kim SG, Dubovi E, Osterrieder N. Investigation of the prevalence of neurologic equine herpes virus type 1 (EHV-1) in a 23-year retrospective analysis (1984-2007). Veterinary Microbiology 2009;139(3-4):375-8
  6. Perkins GA*, Goodman LB*, Dubovi EJ, Kim SG, Osterrieder N. Detection of equine herpesvirus-1 in nasal swabs of horses by quantitative real-time PCR. Journal of Veterinary Internal Medicine 2008; 22(5):1234-8. *Indicates shared first authors
  7. Goodman LB, Loregian A, Perkins GA, Nugent J, Buckles EL, Mercorelli B, Kydd JH, Palù G, Smith KC, Osterrieder N, Davis-Poynter N. A Point Mutation in a Herpesvirus Polymerase Determines Neuropathogenicity. PLoS Pathogens 2007; 3(11):e160
  8. Rosas CT, Tischer BK, Perkins GA, Wagner B, Goodman LB, Osterrieder N. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV)H. Virus Research 2007; 125(1):69-78
  9. Goodman LB, Wagner B, Flaminio MJ, Sussman KH, Metzger SM, Holland R, Osterrieder N. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine 2006; 24(17):3636-45
  10. Rosas CT, Goodman LB, von Einem J, Osterrieder N. Equine herpesvirus type 1 modified live virus vaccines: quo vaditis? Expert Review of Vaccines 2006; 5:119-31
  11. Kasoumov T, Brunengraber LL, Comte B, Puchowicz M, Jobbins K, Thomas K, David F, Kinman R, Wehrli S, Dahms W, Kerr D, Nissim I, Brunengraber H. New secondary metabolites of phenylbutyrate in humans and rats. Drug Metabolism and Disposition 2004; 32(1):10-9
  12. Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber LL, Hines RN, McCarver DG. Human hepatic CYP2E1 expression during development. Journal of Pharmacology and Experimental Therapeutics 2003; 307(1):402-7